Regeneron (REGN) jumps on robust Q4 earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St futures muted as bond yields resume climb; Walmart drops after results
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Crypto stocks surge as Bitcoin short squeeze hits record $2.7B
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Regeneron beats fourth-quarter revenue estimates
February 2, 2024 6:49 AM EST(Reuters) -Regeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker's preliminary estimates target.
Eylea sales were $1.46 billion, including $123 million from the higher dose version of the drug, in line with the company's previously laid out targets in January.
... MoreRegeneron (REGN) Tops Q4 EPS by 109c
February 2, 2024 6:34 AM ESTRegeneron (NASDAQ: REGN) reported Q4 EPS of $11.86, $1.09 better than the analyst estimate of $10.77. Revenue for the quarter came in at $3.43 billion versus the consensus estimate of $3.3 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More